mdlinx mdlinx
Latest (9) Full Text Articles (1364) Focus on Renal Article Summary

Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: A phase III study
Medical Oncology,  Clinical Article

Halim AAF et al. – The objective of this study was to compare concomitant chemoradiotherapy based on weekly low-dose gemcitabine versus weekly low-dose paclitaxel in locally advanced head and neck squamous cell carcinoma. The regimen based on paclitaxel was significantly more tolerable and effective; however, the difference was not enormous.

Methods

  • Previously untreated patients with locally advanced squamous cell carcinoma of head and neck randomly assigned to 1 of 2 concomitant chemoradiation regimens: (1) weekly gemcitabine at dose of 100 mg/m2 over 30 min 1–2 h before radiotherapy and (2) weekly paclitaxal at dose of 20 mg/m2 over 60 min 4–6 h before radiotherapy
  • Planned radiotherapy dose 65 Gy over 6.5 weeks in 32 settings
  • 216 patients were randomly divided into 2 groups: group A (110 patients) and group B (106 patients) who received concomitant weekly low-dose gemcitabine and low-dose paclitaxal, respectively, with radiotherapy protocol

Results
  • Hematological toxicity generally mild
  • Non-hematologic toxicities severe
  • Grade III mucositis occurred in 36% in group A and in 24% in group B (P = 0.04)
  • Moreover, grade III dermatitis were encountered in 24% in group A and 13% in group B (P = 0.049)
  • Thirty-two (29%) of group A and 18(17%) of group B patients required enteral or parenteral feeding (P = 0.01)
  • Sixteen (15%) of group A and 6 (6%) of group B required enteral or parenteral feeding that lasted for 6 months (P = 0.03)
  • Regarding late effect on swallowing, 8% of patients in group A and 2% of patients in group B required enteral or parenteral feeding for more than 6 months (P = 0.035)
  • Response rates 78 and 89% in groups A and B (P = 0.038)
  • 2-year PFAS figures 54 and 64% of groups A and B
  • 2-year OS figures 56 and 67%
  • 3-year PFS figures 39 and 48% for groups A and B
  • Both concomitant chemoradiotherapy regimens easily given in outpatient clinic

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

Last month's top read Top Articles of 2013

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Other Topics in Oncology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow
Like

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close